such as benzodiazepines, and
behavioural treatments (for
example, relaxation techniques)
can be just as effective and the
pharmacist can highlight these
options to a patient who might be
suffering from this.
Conclusions
Pharmacists play a vital role in
the multidisciplinary team that
works with patients receiving
chemotherapy treatments to help
reduce the suffering and anxiety
caused by nausea and vomiting.
Some roles are carried out as soon
as new chemotherapy treatments
are introduced to ensure that
appropriate prophylaxis is built
into electronic prescribing
protocols and hospital guidelines
or to incorporate new antiemetics
into practice. Other roles are
patient-facing to ensure that
all relevant factors have been
accounted for when individualising
a patient’s antiemetic management
plan and ensuring that patients
know how to take their medicines
correctly.
References
1 Hesketh PJ. Chemotherapy-induced nausea
and vomiting. N Engl J Med 2008;358:2482–94.
2 Longo F et al. Combination of aprepitant,
palonosetron and dexamethasone as
antiemetic prophylaxis in lung cancer patients
receiving multiple cycles of cisplatin-based
chemotherapy. International J Clin Pract
2012;66(8):753–7.
3 Cheater FM, Closs SJ. The effectiveness of
methods of dissemination and implementation
of clinical guidelines for nursing practice: a
selective review. Clin Effect Nurs 1997;1:4–15.
4 Darling G. The impact of clinical practice
guidelines and clinical trials on treatment
decisions. Surg Oncol 2002;11:255–62.
5 Hewitt-Taylor J. Clinical guidelines and
care protocols. Intensive Crit Care Nurs
2004;20:45–52.
6 Sekine I et al. Risk factors of chemotherapy-
induced nausea and vomiting: Index for
personalized antiemetic prophylaxis. Cancer
Science 2013;104(6):711–17.
7 Roila F et al. 2016 MASCC and ESMO guideline
update for the prevention of chemotherapy- and
radiotherapy-induced nausea and vomiting and
of nausea and vomiting in advanced cancer
patients. Ann Oncol 2016;27(Supplement
5):v119–v133.
8 National Comprehensive Cancer Network.
Antiemesis v3.2018. www.nccn.org/
professionals/physician_gls/pdf/antiemesis.pdf
(accessed August 2018).
9 Hesketh P J et al. Antiemetics: American Society
of Clinical Oncology Clinical Practice Guideline
Update. J Clin Oncol 2017;35(28)3240–61.
10 Aapro M, Walko CM. Aprepitant: drug–
drug interactions in perspective. Ann Oncol
2010;21(12):2316–23.
11 Pagano G et al. Glucose intolerance after
short-term administration of corticosteroids
in healthy subjects. Prednisone, deflazacort,
and betamethasone. Arch Intern Med
1989;149(5):1098–101.
12 Aapro M et al. A randomised phase III study
evaluating the efficacy and safety of NEPA,
a fixed dose combination of netupitant and
palonosetron, for prevention of chemotherapy-
induced nausea and vomiting following
moderately emetogenic chemotherapy. Ann
Oncol 2014;25:1328–33.
13 Gralla RJ et al. A phase III study evaluating
the safety and efficacy of NEPA, a fixed-dose
combination of netupitant and palonosetron,
for prevention of chemotherapy-induced
nausea and vomiting over repeated cycles of
chemotherapy. Ann Oncol 2014;25:1333–9.
14 Blenkinsopp A, Paxton P, Blenkinsopp
J. Symptoms in the Pharmacy, 5th
Edition;2005:92–4.
15 Roscoe JA et al. Anticipatory nausea
and vomiting. Support Care Cancer
2011;19(10):1533–8.
16 Molassiotis A et al. Anticipatory nausea,
risk factors, and its impact on chemotherapy-
induced nausea and vomiting: Results from the
Pan European Emesis Registry Study. J Pain
Symptom Manage 2016;51:987–93.
hospitalpharmacyeurope.com | 2018 | 83